iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
August 20 2024 - 8:30AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients,
today announced that interim data from GALAXIES Lung-201, the Phase
2 platform study sponsored by iTeos’ development partner GSK,
assessing the belrestotug + dostarlimab doublet in previously
untreated, unresectable, locally advanced or metastatic PD-L1 high
non-small cell lung cancer, will be presented as a late-breaking
oral presentation at the European Society for Medical Oncology
(ESMO) Congress 2024, being held September 13-17, 2024 in
Barcelona, Spain.
Late Breaking Oral Presentation
DetailsTitle: Interim Analysis of
GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study
of Belrestotug Plus Dostarlimab in Patients (pts) With Previously
Untreated Locally Advanced/Metastatic (LA/M) PD-L1 High (TPS
>/=50%) Non-Small Cell Lung Cancer (NSCLC)Abstract
Number: LBA52Session Title: Proffered
Paper Session: NSCLC MetastaticDate / Time:
September 14, 2024 at 8:30 am CEST / 2:30 am ET
The ESMO website indicates that all
late-breaking abstracts will be published on the ESMO website on
the day of the presentation at 00:05 am CEST.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to restore the immune response
against cancer. The Company’s innovative pipeline includes three
clinical-stage programs targeting novel, validated
immunosuppressive pathways designed with optimized pharmacologic
properties for improved clinical outcomes, including the
TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is
headquartered in Watertown, MA with a research center in Gosselies,
Belgium.
About Belrestotug (EOS-448/
GSK4428859A)Belrestotug is an Fc active human
immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T
cell immunoglobulin and immunoreceptor tyrosine-based inhibitory
motif domains (TIGIT), an important inhibitory receptor which
contributes to the suppression of innate and adaptive immune
responses against cancer. As an optimized high-affinity, potent
anti-TIGIT mAb, belrestotug is designed to enhance the antitumor
response through a multifaceted immune modulatory mechanism by
engaging with TIGIT and FcγR, a key regulator of immune responses
which induces cytokine release and antibody dependent cellular
cytotoxicity (ADCC). The therapeutic candidate is progressing in
multiple indications in collaboration with GSK.
Internet Posting of Information
iTeos routinely posts information that may be
important to investors in the 'Investors' section of its website
at www.iteostherapeutics.com. The Company encourages investors
and potential investors to consult our website regularly for
important information about iTeos.
For further information, please contact:
Investor Contact:Carl MauchiTeos Therapeutics,
Inc.carl.mauch@iteostherapeutics.com
Media Contact:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2024 to Oct 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Oct 2023 to Oct 2024